Browse

Molecular characterization and prognostic significance of FLT3 in CML progression

DC Field Value Language
dc.contributor.authorKim, Kyung Im-
dc.contributor.authorPark, Juwon-
dc.contributor.authorAhn, Kwang-Sung-
dc.contributor.authorWon, Nam-Hee-
dc.contributor.authorShin, Wan Gyoon-
dc.contributor.authorOh, Jung Mi-
dc.contributor.authorYoon, Sung-Soo-
dc.contributor.authorKim, Byoung Kook-
dc.date.accessioned2012-05-25T05:51:48Z-
dc.date.available2012-05-25T05:51:48Z-
dc.date.issued2010-08-
dc.identifier.citationLEUKEMIA RESEARCH; Vol.34 8; 995-1001ko_KR
dc.identifier.issn0145-2126-
dc.identifier.urihttps://hdl.handle.net/10371/76468-
dc.description.abstractTo characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfection analysis was conducted to evaluate the role of FLT3, which was significantly upregulated in the blast crisis patients. Abl and c-Kit induction was detected in K562 cells transfected with FLT3 cDNA (K562/FLT3), and Abl and c-Kit levels were reduced in K562/FLT3 cells transfected with FLT3-siRNA (K562/FLT3-siRNA). The induction of FLT3 in CML cells attenuated imatinib-induced apoptosis. The opposite effect was observed in K562/FLT3-siRNA cells. An increased level of cleaved PARP and decreased level of pro-caspase 3 were noted when K562/FLT3-siRNA cells were treated with imatinib. These findings indicate that FLT3 is associated with disease progression, despite imatinib therapy. These results may help in the prediction of disease progression in CML patients and the development of more appropriate therapeutic modalities. (C) 2009 Elsevier Ltd. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDko_KR
dc.subjectChronic myelogenous leukemia (CML)ko_KR
dc.subjectFms-related tyrosine kinase 3 (FLT3)ko_KR
dc.subjectImatinibko_KR
dc.subjectDisease progressionko_KR
dc.subjectResistanceko_KR
dc.titleMolecular characterization and prognostic significance of FLT3 in CML progressionko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김경임-
dc.contributor.AlternativeAuthor박주원-
dc.contributor.AlternativeAuthor안광성-
dc.contributor.AlternativeAuthor원남희-
dc.contributor.AlternativeAuthor김병국-
dc.contributor.AlternativeAuthor신완균-
dc.contributor.AlternativeAuthor윤성수-
dc.contributor.AlternativeAuthor오정미-
dc.identifier.doi10.1016/j.leukres.2009.11.008-
dc.citation.journaltitleLEUKEMIA RESEARCH-
dc.description.citedreferenceHoshino K, 2009, LEUKEMIA RES, V33, P1361, DOI 10.1016/j.leukres.2009.03.044-
dc.description.citedreferenceVolpe G, 2009, CANCER LETT, V274, P1, DOI 10.1016/j.canlet.2008.06.003-
dc.description.citedreferencePeng HL, 2008, CROAT MED J, V49, P650, DOI 10.3325/cmj.2008.5.650-
dc.description.citedreferenceMatsumura I, 2008, CANCER SCI, V99, P479, DOI 10.1111/j.1349-7006.2007.00717.x-
dc.description.citedreferenceKim BS, 2007, ANTI-CANCER DRUG, V18, P641-
dc.description.citedreferenceRadich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103-
dc.description.citedreferenceYong ASM, 2006, BLOOD, V107, P205, DOI 10.1182/blood-2005-05-2155-
dc.description.citedreferenceMarkovic A, 2005, INT J BIOCHEM CELL B, V37, P1168, DOI 10.1016/j.biocel.2004.12.005-
dc.description.citedreferenceILARIA RL, 2005, HEMATOLOGY AM SOC HE, P188-
dc.description.citedreferenceDaub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579-
dc.description.citedreferenceSchmidt-Arras D, 2004, CURR PHARM DESIGN, V10, P1867-
dc.description.citedreferenceKottaridis PD, 2003, BRIT J HAEMATOL, V122, P523-
dc.description.citedreferenceNowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620-
dc.description.citedreferenceMarktel S, 2003, HAEMATOLOGICA, V88, P260-
dc.description.citedreferenceOhmine K, 2003, STEM CELLS, V21, P315-
dc.description.citedreferenceGilliland DG, 2002, CURR OPIN HEMATOL, V9, P274-
dc.description.citedreferenceSawyers CL, 2002, BLOOD, V99, P3530-
dc.description.citedreferenceOhmine K, 2001, ONCOGENE, V20, P8249-
dc.description.citedreferenceSawyers CL, 1999, NEW ENGL J MED, V340, P1330-
dc.description.citedreferenceSavage DG, 1997, BRIT J HAEMATOL, V99, P30-
dc.description.citedreferenceCarow CE, 1996, BLOOD, V87, P1089-
dc.description.citedreferenceSILL H, 1995, BLOOD, V85, P2013-
dc.description.citedreferenceBIRG F, 1992, BLOOD, V80, P2584-
dc.description.citedreferenceAHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783-
dc.description.citedreferenceKANTARJIAN HM, 1987, AM J MED, V83, P445-
dc.description.citedreferenceSOKAL JE, 1984, BLOOD, V63, P789-
dc.description.tc1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse